KR20240105664A - Cosmetic composition for scalp soothing comprising mixture of Camellia japonica pericarp extract and Cynanchum atratum extract as an active ingredient - Google Patents
Cosmetic composition for scalp soothing comprising mixture of Camellia japonica pericarp extract and Cynanchum atratum extract as an active ingredientInfo
- Publication number
- KR20240105664A KR20240105664A KR1020220187605A KR20220187605A KR20240105664A KR 20240105664 A KR20240105664 A KR 20240105664A KR 1020220187605 A KR1020220187605 A KR 1020220187605A KR 20220187605 A KR20220187605 A KR 20220187605A KR 20240105664 A KR20240105664 A KR 20240105664A
- Authority
- KR
- South Korea
- Prior art keywords
- scalp
- extract
- hair
- camellia
- cosmetic composition
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 152
- 210000004761 scalp Anatomy 0.000 title claims abstract description 131
- 240000001548 Camellia japonica Species 0.000 title claims abstract description 56
- 239000000203 mixture Substances 0.000 title claims abstract description 51
- 239000004480 active ingredient Substances 0.000 title claims abstract description 25
- 239000002537 cosmetic Substances 0.000 title claims abstract description 25
- 235000006467 Camellia japonica Nutrition 0.000 title description 4
- 241000028204 Vincetoxicum atratum Species 0.000 title description 4
- 241000574138 Ozothamnus diosmifolius Species 0.000 claims abstract description 53
- 235000018597 common camellia Nutrition 0.000 claims abstract description 52
- 230000004888 barrier function Effects 0.000 claims abstract description 30
- 208000003251 Pruritus Diseases 0.000 claims abstract description 23
- 230000007803 itching Effects 0.000 claims abstract description 23
- 206010061218 Inflammation Diseases 0.000 claims abstract description 22
- 230000004054 inflammatory process Effects 0.000 claims abstract description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 47
- 238000005728 strengthening Methods 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 238000009472 formulation Methods 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 239000006071 cream Substances 0.000 claims description 11
- 239000006210 lotion Substances 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 7
- 235000013399 edible fruits Nutrition 0.000 claims description 6
- 239000002453 shampoo Substances 0.000 claims description 5
- 239000003708 ampul Substances 0.000 claims description 2
- 239000000118 hair dye Substances 0.000 claims description 2
- 239000003595 mist Substances 0.000 claims description 2
- 230000001256 tonic effect Effects 0.000 claims description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 abstract description 36
- 229960001340 histamine Drugs 0.000 abstract description 18
- 238000004519 manufacturing process Methods 0.000 abstract description 15
- 210000002510 keratinocyte Anatomy 0.000 abstract description 12
- 230000000770 proinflammatory effect Effects 0.000 abstract description 12
- 102000004127 Cytokines Human genes 0.000 abstract description 11
- 108090000695 Cytokines Proteins 0.000 abstract description 11
- 102100028314 Filaggrin Human genes 0.000 abstract description 11
- 101710088660 Filaggrin Proteins 0.000 abstract description 11
- 210000003630 histaminocyte Anatomy 0.000 abstract description 11
- 230000028327 secretion Effects 0.000 abstract description 10
- 206010040880 Skin irritation Diseases 0.000 abstract description 4
- 230000001737 promoting effect Effects 0.000 abstract description 4
- 230000036556 skin irritation Effects 0.000 abstract description 4
- 231100000475 skin irritation Toxicity 0.000 abstract description 4
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 abstract description 3
- 231100000135 cytotoxicity Toxicity 0.000 abstract description 3
- 230000003013 cytotoxicity Effects 0.000 abstract description 3
- 230000000694 effects Effects 0.000 description 24
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 18
- 239000004615 ingredient Substances 0.000 description 16
- 210000003491 skin Anatomy 0.000 description 15
- 239000002904 solvent Substances 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 239000008213 purified water Substances 0.000 description 10
- 210000002374 sebum Anatomy 0.000 description 10
- -1 pregnane glycosides Chemical class 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 239000002131 composite material Substances 0.000 description 8
- 239000003755 preservative agent Substances 0.000 description 8
- 238000007796 conventional method Methods 0.000 description 7
- 239000003205 fragrance Substances 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000002137 ultrasound extraction Methods 0.000 description 6
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 102100040247 Tumor necrosis factor Human genes 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000000049 pigment Substances 0.000 description 5
- 230000009257 reactivity Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 208000008742 seborrheic dermatitis Diseases 0.000 description 5
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 5
- 210000000434 stratum corneum Anatomy 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 4
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 4
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 4
- 208000001840 Dandruff Diseases 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 4
- 239000005642 Oleic acid Substances 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 4
- 239000010495 camellia oil Substances 0.000 description 4
- 230000001186 cumulative effect Effects 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 4
- 230000005722 itchiness Effects 0.000 description 4
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000006748 scratching Methods 0.000 description 4
- 230000002393 scratching effect Effects 0.000 description 4
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 235000013871 bee wax Nutrition 0.000 description 3
- 239000012166 beeswax Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 235000021588 free fatty acids Nutrition 0.000 description 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 241000587240 Cynanchum Species 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 108700041153 Filaggrin Proteins Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000555676 Malassezia Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 229960000458 allantoin Drugs 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- LRFDUPNLCDXZOE-UHFFFAOYSA-N camellianin b Chemical compound OC1C(O)C(O)C(C)OC1OC1C(O)C(O)C(OC=2C=3C(=O)C=C(OC=3C=C(O)C=2)C=2C=CC(O)=CC=2)OC1CO LRFDUPNLCDXZOE-UHFFFAOYSA-N 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- MRUAUOIMASANKQ-UHFFFAOYSA-N cocamidopropyl betaine Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O MRUAUOIMASANKQ-UHFFFAOYSA-N 0.000 description 2
- 229940073507 cocamidopropyl betaine Drugs 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 2
- 239000000686 essence Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 208000024963 hair loss Diseases 0.000 description 2
- 230000003676 hair loss Effects 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- GSGDTSDELPUTKU-UHFFFAOYSA-N nonoxybenzene Chemical compound CCCCCCCCCOC1=CC=CC=C1 GSGDTSDELPUTKU-UHFFFAOYSA-N 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229940068977 polysorbate 20 Drugs 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 230000008591 skin barrier function Effects 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000000106 sweat gland Anatomy 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 230000002087 whitening effect Effects 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 1
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000219104 Cucurbitaceae Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- ZRVSAJIGCDWADZ-UHFFFAOYSA-N Leucoanthocyanin Natural products OCC1OC(CC(O)C1O)OC2C(O)c3c(O)cc(O)cc3OC2c4ccc(O)c(O)c4 ZRVSAJIGCDWADZ-UHFFFAOYSA-N 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- VBIIFPGSPJYLRR-UHFFFAOYSA-M Stearyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)C VBIIFPGSPJYLRR-UHFFFAOYSA-M 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- PYIDGJJWBIBVIA-UYTYNIKBSA-N lauryl glucoside Chemical compound CCCCCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O PYIDGJJWBIBVIA-UYTYNIKBSA-N 0.000 description 1
- 229940048848 lauryl glucoside Drugs 0.000 description 1
- 230000003520 lipogenic effect Effects 0.000 description 1
- 230000002366 lipolytic effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 239000013081 microcrystal Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- BOUCRWJEKAGKKG-UHFFFAOYSA-N n-[3-(diethylaminomethyl)-4-hydroxyphenyl]acetamide Chemical compound CCN(CC)CC1=CC(NC(C)=O)=CC=C1O BOUCRWJEKAGKKG-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000021315 omega 9 monounsaturated fatty acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 229940104261 taurate Drugs 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
Abstract
본 발명은 동백나무 과피 추출물과 백미꽃 추출물을 유효성분으로 포함하는 두피 진정용 화장료 조성물에 관한 것이다.
본 발명에 따른 조성물은 피부자극 및 세포독성이 없어 인체 안전성이 우수하면서도 비만세포의 히스타민 분비를 억제하고, 각질형성세포의 필라그린 생성을 촉진하고, 각질형성세포의 전염증성 사이토카인 발현을 억제함으로써 두피의 가려움증을 완화하고 두피의 장벽을 강화시키고, 두피의 염증을 개선하여 문제성 두피를 진정할 수 있어 두피 진정용 화장료 조성물로 유용하다.The present invention relates to a cosmetic composition for soothing the scalp containing camellia pericarp extract and white rice flower extract as active ingredients.
The composition according to the present invention is free from skin irritation and cytotoxicity and has excellent human safety, while suppressing histamine secretion from mast cells, promoting filaggrin production from keratinocytes, and suppressing the expression of pro-inflammatory cytokines from keratinocytes. It is useful as a cosmetic composition for soothing the scalp as it can relieve scalp itching, strengthen the scalp barrier, and improve scalp inflammation to soothe problematic scalp.
Description
본 발명은 동백나무 과피 추출물과 백미꽃 추출물을 유효성분으로 포함하는 두피 진정용 조성물에 관한 것이다. 보다 상세하게는, 외부 자극으로부터 두피 가려움증을 억제하고 두피 장벽기능을 강화하여 두피를 진정시킬 수 있는, 동백나무 과피 추출물 및 백미꽃 추출물을 유효성분으로 포함한 두피 진정용 화장료 조성물에 관한 것이다.The present invention relates to a composition for soothing the scalp containing camellia pericarp extract and white rice flower extract as active ingredients. More specifically, it relates to a cosmetic composition for soothing the scalp containing camellia pericarp extract and white rice flower extract as active ingredients, which can suppress scalp itchiness from external stimuli and soothe the scalp by strengthening the scalp barrier function.
현대사회를 살아가는 사람들의 두피는 미세먼지와 황사 등의 각종 환경오염에 노출되어 있다. 이와 함께 염색, 탈색, 퍼머, 드라이 등의 미용적 시술은 두피에 자극과 손상을 유발시키게 된다. 또한, 과도한 업무로 인한 피로와 스트레스, 불규칙한 생활습관 등으로 인해 두피 관련 질환은 더욱 가속화되고 있는 추세이다.The scalp of people living in modern society is exposed to various environmental pollution such as fine dust and yellow dust. In addition, cosmetic procedures such as dyeing, bleaching, perming, and drying cause irritation and damage to the scalp. In addition, scalp-related diseases are accelerating due to fatigue and stress caused by excessive work, irregular lifestyle habits, etc.
두피는 두부(頭部)를 보호하고 있는 피부조직으로, 모근부(毛根部)와 한선(汗腺)이 발달되어 있다. 두피의 모근부는 피부 속에 있는 모발 부위로 피지선을 가지며 피지를 분비하여 수분 증발과 세균 감염으로부터 막아 주며, 한선은 땀을 배출하여 체온 조절을 하게 된다. 피부에 적절한 피지 분비는 피부를 보호하고 아름다운 윤기를 주는 반면, 과다하게 생성된 피지는 피부의 번들거림이나 여드름, 지루성 피부염 등의 만성 염증을 유발하게 된다. 피지분비는 성 호름몬인 안드로겐의 과다분비, 레티노이드(retinoid) 및 리포제닉 유전자(lipogenic gene) 발현을 조절하는 PPARγ(peroxidome proliferator activated receptor γ), Wnt(Wingless) 신호, 인슐린 등이 관여하는 것으로 알려져 있으며, 최종적으로 지질의 합성이나 피지 세포의 분화 기전에 의해 조절된다. 특히 두피에 피지가 과도하게 생성되면 지루성 두피염으로 발달할 가능성이 높은데, 지루성 두피염은 홍반과 함께 인설 및 비듬을 동반하며 가려움과 염증을 유발하는 환경을 만들게 된다. 그러므로, 지루성 두피염을 제대로 치료하지 않을 경우 만성적인 두피 염증 질환뿐만 아니라 탈모까지 유발할 수 있다.The scalp is a skin tissue that protects the head and has developed hair roots and sweat glands. The hair root of the scalp is the hair area within the skin and has sebaceous glands that secrete sebum to prevent moisture evaporation and bacterial infection, while sweat glands regulate body temperature by producing sweat. Proper sebum secretion in the skin protects the skin and gives it a beautiful glow, while excessively produced sebum causes chronic inflammation such as shiny skin, acne, and seborrheic dermatitis. Sebum secretion is known to be involved in hypersecretion of androgens, which are sex hormones, PPARγ (peroxidome proliferator activated receptor γ), which regulates the expression of retinoid and lipogenic genes, Wnt (Wingless) signal, and insulin. and is ultimately regulated by lipid synthesis or sebum cell differentiation mechanisms. In particular, if sebum is excessively produced on the scalp, there is a high possibility of developing seborrheic dermatitis. Seborrheic dermatitis is accompanied by erythema, scaling, and dandruff, creating an environment that causes itching and inflammation. Therefore, if seborrheic dermatitis is not treated properly, it can cause not only chronic scalp inflammatory disease but also hair loss.
두피에 존재하는 말라세지아(Malasezia)는 다른 병원성 진균에 비해 상대적으로 두피의 피지를 분해하는 지질분해 효소를 많이 보유하고 있다고 보고되고 있다. 말라세지아는 중성지방(Triglyceride)과 에스테르(Ester)로 구성된 디글리세라이드(Diglyceride)를 모노글리세라이드(Monoglyceride)와 유리지방산(free fatty acids)으로 분해하는데, 말라세지아는 이 과정에서 생성된 포화유리지방산(saturated free fatty acids)을 먹고 나머지는 대사 잔여물로 남기게 된다. 이러한 대사 잔여물 중 불포화지방산(saturated free fatty acids)은 두피 상피세포층을 파괴하고 각질층 형성을 비정상적으로 촉진시켜 비듬을 유발시키는 것으로 알려져 있다. 이 같은 과정은 두피의 장벽기능 손상을 유발하게 되고, 이로 인해 두피 장벽의 항상성 유지가 힘들어 지므로, 외부 자극에 대해 민감해지게 되고, 두피의 유분과 수분의 균형도 깨지게 진다. 불포화지방산인 올레인산(oleic acid)은 두피의 비만세포를 자극하여 히스타민, 프로테아제(protease) 등을 분비함으로써 가려움증과 염증을 유발시키고, 가려움에 따른 긁음 등의 물리적 자극은 2차 세균 감염으로 이어지기도 한다. 또한 포화지방산인 팔미트산(palmitic acid)은 피지세포에서 지질 합성을 촉진하고 염증반응을 일으킨다고 연구 결과가 있다.Malasezia, which exists on the scalp, is reported to have a relatively large amount of lipolytic enzymes that decompose sebum on the scalp compared to other pathogenic fungi. Malassezia decomposes diglycerides, which are composed of triglycerides and esters, into monoglycerides and free fatty acids. Malassezia is the saturated glass produced in this process. We eat fatty acids (saturated free fatty acids) and leave the rest as metabolic residue. Among these metabolic residues, saturated free fatty acids are known to cause dandruff by destroying the scalp epithelial cell layer and abnormally promoting the formation of the stratum corneum. This process causes damage to the scalp's barrier function, making it difficult to maintain homeostasis of the scalp barrier, making it sensitive to external stimuli, and disrupting the balance of oil and moisture in the scalp. Oleic acid, an unsaturated fatty acid, stimulates mast cells in the scalp to secrete histamine and protease, causing itching and inflammation, and physical stimulation such as scratching due to itching may lead to secondary bacterial infection. . Additionally, studies have shown that palmitic acid, a saturated fatty acid, promotes lipid synthesis in sebum cells and causes inflammatory reactions.
문제성 두피의 일반적인 특징은 피부의 표층인 각질층(stratum corneum)에서 나타난다. 각질층은 미생물, 독성물질, 산화제 및 자외선에 의한 병원성 침입에 대한 장벽 역할을 한다. 이와 함께 각질층의 가장 중요한 역할은 수분 손실에 대한 장벽 역할을 하는 것이다. 가장 기본적인 이러한 기능의 손실은 표피 투과성 장벽(epidermal permeability barrier)으로서의 기능 소실을 의미한다. 각질층 내에서 수분 균형을 유지하는데 도움이 되는 필수인자로는 천연보습인자(NMF)가 있는데, 이는 피부 각질형성세포 분화과정에서 필라그린(filaggrin)이 분해돼서 생성되는 인자이다. 필라그린은 각질형성세포의 케라틴이 서로 뭉쳐질 수 있도록 돕는 물질로 피부장벽을 형성하고 구조를 견고하게 유지할 수 있게 결집시켜주는 단백질이다. 그러므로, 이러한 장벽 기능의 강화는 외부 자극으로부터 두피를 보호하고 두피 염증을 예방할 수 있는 두피 진정 소재 개발의 타겟이 되고 있다.The general characteristics of problematic scalp appear in the stratum corneum, the superficial layer of the skin. The stratum corneum serves as a barrier against pathogenic invasion by microorganisms, toxins, oxidants, and ultraviolet rays. At the same time, the most important role of the stratum corneum is to act as a barrier against moisture loss. The loss of this most basic function means loss of function as an epidermal permeability barrier. An essential factor that helps maintain moisture balance within the stratum corneum is natural moisturizing factor (NMF), which is produced by the breakdown of filaggrin during the differentiation of skin keratinocytes. Filaggrin is a substance that helps the keratin of keratinocytes to come together. It is a protein that forms a skin barrier and holds the structure firmly together. Therefore, strengthening this barrier function has become a target for the development of scalp soothing materials that can protect the scalp from external stimuli and prevent scalp inflammation.
현재 두피 염증과 가려움증을 치료하기 위해서 항진균제, 스테로이드, 면역조절 물질 등이 사용되고 있으나, 안전하고 효과적이면서 장기간 사용할 수 있는 치료제는 거의 없는 실정으로 시장 요구도는 갈수록 증가하고 있다. 따라서 내·외부 자극으로부터 유발되는 염증과 가려움증을 억제하거나 피부장벽 기능을 강화함으로써 두피 문제를 개선 또는 완화하려는 시도들이 이루어지고 있다.Currently, antifungal agents, steroids, and immunomodulatory substances are used to treat scalp inflammation and itching, but there are few treatments that are safe, effective, and can be used for a long time, and market demand is increasing. Therefore, attempts are being made to improve or alleviate scalp problems by suppressing inflammation and itching caused by internal and external stimuli or strengthening the skin barrier function.
동백나무(Camillia japonica L.)는 차나무과에 속하는 상록 교목으로 수많은 원예품종이 만들어져 대부분 관상수이거나 종자에서 짜낸 동백기름으로 이용되었다. 동백꽃은 생리활성이 뛰어난 류코안토시아닌(leucoanthocyanin), 안토시아닌(anthocyanin)이 함유되어 있으며, 과실에는 지방유, 카멜린(camellin), 타키사포닌(thachysaponin)이 들어있다. 예부터 머리 기름으로 많이 사용된 동백 오일은 오메가-9인 올레인산(oleic acid)이 80% 정도 포함되어 있으며, 그 밖에도 폴리페놀(polyphenols), 비타민 A, C, D, E와 다른 항산화물질도 포함하고 있다고 알려져 있다. 이런 이차대사산물들은 강심작용과 양혈, 지혈, 산어, 소종 등의 효능이 있다고 알려져 있다. Camellia japonica L. is an evergreen tree belonging to the Camellia family. Numerous horticultural varieties have been created, and most of them have been used as ornamental trees or as camellia oil extracted from seeds. Camellia flowers contain leucoanthocyanin and anthocyanin, which have excellent physiological activity, and the fruit contains fatty oil, camellin, and thachysaponin. Camellia oil, which has been widely used as hair oil since ancient times, contains about 80% oleic acid, an omega-9, and also contains polyphenols, vitamins A, C, D, E and other antioxidants. It is known that they are doing it. These secondary metabolites are known to have effects such as cardiotonic effect, hemostasis, hemostasis, live fish, and small intestine.
상기 동백나무 효능과 관련하여 대한민국 등록특허 제10-1672431호는 동백나무 추출물의 심혈관계 질환 예방효과를 개시하고 있고, 대한민국 등록특허 제10-1408019호는 동백나무 열매 추출물의 항산화 및 미백효과를, 대한민국 제10-1452320호는 동백오일의 탈모개선 효과를 개시하고 있으나, 아직까지 동백나무 과피 추출물(Camellia japonica pericarp extract)의 두피 가려움증 완화, 두피 장벽 강화 등의 두피 개선 효능에 관해서는 밝혀진 바가 없다.Regarding the efficacy of camellia tree, Republic of Korea Patent No. 10-1672431 discloses the cardiovascular disease prevention effect of camellia tree extract, and Republic of Korea Patent No. 10-1408019 discloses the antioxidant and whitening effect of camellia fruit extract, Republic of Korea No. 10-1452320 discloses the hair loss improvement effect of camellia oil, but nothing has yet been revealed about the scalp improvement effects of Camellia japonica pericarp extract, such as relieving scalp itchiness and strengthening the scalp barrier.
백미꽃(Cynanchum atratum Bunge)은 박주가리과 백미꽃속의 다년생 초본식물로 진한 보라색꽃을 피우며, 관상용 및 약용으로서 이용되고 있다. 뿌리는 해열작용이 있어서 폐결핵으로 조열, 혈열, 허열, 토혈, 신장염, 요로감염증 등에 효능이 있다고 알려져 있다. 백미꽃의 뿌리에서 발견되는 바이페닐네오리그난(biphenylneolignan), 프로그난 글리코사이드(pregnane glycosides) 등은 항염, 항아토피, 항진균, 멜라닌 생성 억제효능을 나타낸다고 보고되어 있다.White rice flower ( Cynanchum atratum Bunge) is a perennial herbaceous plant of the genus Cynanchum in the family Cucurbitaceae. It blooms dark purple flowers and is used for ornamental and medicinal purposes. The root has an antipyretic effect and is known to be effective in pulmonary tuberculosis, premature fever, blood fever, ischemic fever, hematemesis, nephritis, and urinary tract infections. Biphenylneolignan and pregnane glycosides found in the roots of white rice flowers are reported to have anti-inflammatory, anti-atopic, anti-fungal, and melanin production-inhibiting effects.
상기 백미꽃 효능과 관련하여 대한민국 등록특허 제10-1285234호는 백미꽃 추출물의 관절염 예방 및 치료 효능을 개시하고 있고, 대한민국 등록특허 제10-1047588호는 백미꽃 추출물의 미백 효과를, 대한민국 등록특허 제10-1493461호는 백미꽃 추출물의 결핵 치료 효과를, 대한민국 등록 특허 제10-1179966호는 백미꽃 추출물을 포함하는 복합 추출물의 항염 효과에 대해서 개시하고 있으나, 아직까지 백미꽃 추출물의 두피 가려움증 억제, 두피 장벽 강화 등의 두피 개선 효능에 대해서는 밝혀진 바가 없다.Regarding the efficacy of white rice flowers, Republic of Korea Patent No. 10-1285234 discloses the efficacy of white rice flower extract in preventing and treating arthritis, and Republic of Korea Patent No. 10-1047588 discloses the whitening effect of white rice flower extract, and Korea Patent No. 10- No. 1493461 discloses the tuberculosis treatment effect of white rice flower extract, and Republic of Korea Patent No. 10-1179966 discloses the anti-inflammatory effect of a complex extract containing white rice flower extract, but there is still no evidence for white rice flower extract, such as suppressing scalp itching and strengthening the scalp barrier. Nothing has been revealed about its effectiveness in improving the scalp.
이에 본 발명자들은 외부 자극으로부터 유발된 두피의 가려움증 억제, 및 두피의 장벽기능 강화를 통한 문제성 두피의 개선 소재를 찾는 연구를 수행하였으며, 동백나무 과피 추출물과 백미꽃 추출물을 혼합한 복합 추출물이 다른 어떠한 소재에 비하여 문제성 두피의 개선에 우수한 효능을 가지고 있음을 발견하고 이에 따라 본 발명을 완성하게 되었다.Accordingly, the present inventors conducted research to find a material for improving problematic scalp by suppressing itching of the scalp caused by external stimuli and strengthening the barrier function of the scalp, and found that a composite extract of camellia pericarp extract and white rice flower extract is superior to any other material. It was discovered that it has excellent efficacy in improving problematic scalp compared to other products, and thus the present invention was completed.
본 발명의 목적은 동백나무 과피 추출물 및 백미꽃 추출물을 유효성분으로 포함하는, 두피 가려움증 완화, 두피 장벽의 기능 강화, 및 두피 염증의 개선에 따른 두피 진정용 화장료 조성물을 제공하기 위한 것이다.The purpose of the present invention is to provide a cosmetic composition for soothing the scalp by relieving scalp itching, strengthening the function of the scalp barrier, and improving scalp inflammation, comprising camellia pericarp extract and white rice flower extract as active ingredients.
상기 목적을 달성하기 위해, 본 발명은 동백나무 과피 추출물 및 백미꽃 추출물물을 유효성분으로 포함하는, 두피 가려움증 완화, 두피 장벽의 기능 강화, 및 두피 염증의 개선에 따른 두피 진정용 화장료 조성물을 제공한다.To achieve the above object, the present invention provides a cosmetic composition for soothing the scalp by alleviating scalp itching, strengthening the function of the scalp barrier, and improving scalp inflammation, comprising camellia pericarp extract and white rice flower extract as active ingredients. .
본 발명의 동백나무 과피 추출물 및 백미꽃 추출물을 유효성분으로 포함하는 조성물은 피부자극 및 세포독성이 없어 인체 안전성이 우수하면서도 비만세포의 히스타민 분비를 억제하여 가려움증을 완화하고, 두피 장벽기능의 강화를 통해 두피 장벽의 항상성을 유지하며, 두피 염증을 유발하는 전염증성 사이토카인의 생성을 억제하는데 매우 효과적이므로, 두피 진정용 화장료 조성물로서 유용하게 이용될 수 있다.The composition containing camellia pericarp extract and white rice flower extract of the present invention as active ingredients has no skin irritation or cytotoxicity, so it has excellent human safety, suppresses histamine secretion from mast cells, relieves itching, and strengthens the scalp barrier function. Since it is very effective in maintaining the homeostasis of the scalp barrier and inhibiting the production of pro-inflammatory cytokines that cause scalp inflammation, it can be usefully used as a cosmetic composition for soothing the scalp.
도 1은 본 발명의 일 실시예에 따른 동백나무 과피와 백미꽃 각각의 추출물과 동백나무과피 추출물과 백미꽃 추출물 복합 추출물의 비만세포의 히스타민 분비 억제 효과를 나타내는 그림이다.
도 2는 본 발명의 일 실시예에 따른 동백나무 과피 추출물과 백미꽃 추출물의 복합 추출물에 의한 필라그린 mRNA 발현 촉진 효과를 나타낸 그래프이다.
도 3는 본 발명의 일 실시예에 따른 동백나무 과피 추출물과 백미꽃 추출물의 복합 추출물에 의한 각질형성세포의 전염증성 사이토카인 발현 억제를 나타낸 그래프이다. Figure 1 is a diagram showing the inhibitory effect of histamine secretion in mast cells of each extract of camellia pericarp and white rice flower extract and the combined extract of camellia pericarp extract and white rice flower extract according to an embodiment of the present invention.
Figure 2 is a graph showing the effect of promoting filaggrin mRNA expression by a complex extract of camellia pericarp extract and white rice flower extract according to an embodiment of the present invention.
Figure 3 is a graph showing the inhibition of pro-inflammatory cytokine expression in keratinocytes by a complex extract of camellia pericarp extract and white rice flower extract according to an embodiment of the present invention.
본 발명은 동백나무 과피 추출물과 백미꽃 추출물을 유효성분으로 포함하는 두피 진정용 화장료 조성물에 관한 것이다. 본 발명에 따른 동백나무 과피 추출물과 백미꽃 추출물의 복합 추출물은 피부자극 및 세포독성이 없어 인체 안전성이 우수하면서도 비만세포의 히스타민 분비를 억제하고, 각질형성세포의 필라그린 생성을 촉진하고, 각질형성세포의 전염증성 사이토카인 발현을 억제함으로써 두피의 가려움증을 완화하고 두피의 장벽을 강화시키고, 두피의 염증을 개선하여 문제성 두피를 진정할 수 있다.The present invention relates to a cosmetic composition for soothing the scalp containing camellia pericarp extract and white rice flower extract as active ingredients. The complex extract of camellia pericarp extract and white rice flower extract according to the present invention has no skin irritation or cytotoxicity, so it has excellent human safety, suppresses histamine secretion from mast cells, promotes the production of filaggrin in keratinocytes, and promotes the production of filaggrin in keratinocytes. By suppressing the expression of pro-inflammatory cytokines, it can relieve scalp itching, strengthen the scalp barrier, and improve scalp inflammation to soothe problematic scalp.
보다 구체적으로, 본 발명은 동백나무 과피추출물과 백미꽃 추출물을 유효성분으로 포함하는, 두피 가려움증 완화, 두피 장벽의 기능 강화, 및/또는 두피 염증의 개선에 따른 두피 진정용 화장료 조성물을 제공한다.More specifically, the present invention provides a cosmetic composition for soothing the scalp by alleviating scalp itching, strengthening the function of the scalp barrier, and/or improving scalp inflammation, comprising camellia pericarp extract and white rice flower extract as active ingredients.
본 발명의 용어 "동백나무(Camillia japonica L.)"는 차나무과에 속하는 상록 교목으로, 수많은 원예품종이 만들어져 대부분 관상수로 재배되거나 종자에서 짜낸 동백기름으로 이용해 온 식물이다.The term " Camellia japonica L." in the present invention is an evergreen tree belonging to the Camellia family. Numerous horticultural varieties have been created and most of them are cultivated as ornamental trees or used for camellia oil squeezed from seeds.
본 발명의 용어 "과피(果皮, pericarp)"는 열매에서 종자를 제외한 나머지 부분을 의미하는 것으로, 본 발명에서는 동백나무의 열매에서 종자(seed)를 제거하고 남은 부분 모두를 의미한다.The term "pericarp" in the present invention refers to the remaining part of the fruit excluding the seeds, and in the present invention, it refers to all parts remaining after removing the seeds from the fruit of the camellia tree.
본 발명의 용어 "백미꽃(Cynanchum atratum Bunge)"는 박주가리과 백미꽃속에 속하는 여러해살이풀이다. 상기 백미꽃은 하기에서 서술하는 추출물을 제조함에 있어서 백미꽃의 다양한 부위, 예를 들어 잎, 뿌리, 줄기, 꽃, 지상부 등을 사용할 수 있으며, 바람직하게는 지상부를 사용할 수 있다.The term " Cynanchum atratum Bunge" in the present invention is a perennial herb belonging to the genus Cynanchum atratum of the Cynanchum family. In producing the extract described below, various parts of the white rice flower, such as leaves, roots, stems, flowers, and above-ground parts, can be used, and the above-ground part is preferably used.
본 발명에서 상기 "추출물(extract)"은 본 발명의 목적에 따라 동백나무 과피 및 백미꽃 각각 또는 이의 혼합물을 다양한 용매에 침지한 다음, 상온 또는 가온상태에서 일정시간 동안 추출, 분획하여 수득한 액상성분, 상기 액상성분으로부터 용매를 제거하여 수득한 고형분 등의 결과물을 의미한다. 뿐만 아니라, 상기 결과물에 더하여, 상기 결과물의 희석액, 이들의 농축액, 이들의 조정제물, 정제물 등을 모두 포함하는 것으로 포괄적으로 해석될 수 있다.In the present invention, the "extract" refers to a liquid component obtained by immersing each or a mixture of camellia pericarp and white rice flower or a mixture thereof in various solvents and then extracting and fractionating them at room temperature or at a heated state for a certain period of time for the purpose of the present invention. , refers to the result, such as solid content, obtained by removing the solvent from the liquid component. In addition, in addition to the above results, it can be comprehensively interpreted to include dilutions of the results, concentrates thereof, crude preparations, purifications, etc. of the above results.
상기 용매는 물 또는 다양한 유기용매일 수 있으며, 두피 가려움증 완화, 두피 장벽 강화 및/또는 두피 염증 개선 효과를 갖는 추출물을 수득할 수 있는 한 특별히 이에 제한되지 않는다. 보다 구체적으로, 상기 용매는 물, 극성용매 또는 비극성용매가 될 수 있고, 바람직하게는 물, 탄소수 1 내지 4의 저급 알코올(에탄올, 메탄올, 프로판올 또는 부탄올 등), 이들의 혼합용매 등이 될 수 있으며, 가장 바람직하게는 에탄올을 사용할 수 있다.The solvent may be water or various organic solvents, and is not particularly limited as long as an extract having the effect of relieving scalp itching, strengthening the scalp barrier, and/or improving scalp inflammation can be obtained. More specifically, the solvent may be water, a polar solvent, or a non-polar solvent, and preferably may be water, a lower alcohol having 1 to 4 carbon atoms (ethanol, methanol, propanol, or butanol, etc.), or a mixed solvent thereof. and, most preferably, ethanol can be used.
또한, 상기 추출물을 수득하기 위한 방법 역시 두피 가려움증 완화, 두피 장벽 강화, 및 두피의 전염증성 사이토카인 생성 억제 효과를 갖는 추출물을 수득할 수 있는 한, 특별히 이에 제한되지 않는다. 추출 방법은 냉침 추출, 초음파 추출, 또는 환류 냉각 추출 방법 등이 있으며, 초음파 추출 방법으로 실시하는 것이 바람직하다.In addition, the method for obtaining the extract is not particularly limited, as long as it is possible to obtain an extract that has the effect of alleviating scalp itching, strengthening the scalp barrier, and inhibiting the production of pro-inflammatory cytokines in the scalp. Extraction methods include cold needle extraction, ultrasonic extraction, or reflux cooling extraction, and it is preferable to use the ultrasonic extraction method.
상기 초음파 추출은 진동수가 1초에 20,000번 이상인 진동소자를 사용하여 각종 천연소재로부터 유용성분을 화학적인 힘이 아닌 물리적인 힘으로 상온에서 추출하는 방법으로, 용매 추출, 식물성 오일 추출 또는 수증기 증류 추출과 달리 상온에서 천연소재가 함유하고 있는 유효성분을 파괴하지 않고 고농도로 추출할 수 있는 장점이 있다.The ultrasonic extraction is a method of extracting useful components from various natural materials at room temperature using physical force rather than chemical force using a vibrating element with a frequency of more than 20,000 times per second. Solvent extraction, vegetable oil extraction, or steam distillation extraction Unlike other methods, it has the advantage of being able to extract high concentrations of active ingredients contained in natural materials at room temperature without destroying them.
하나의 구체적 예로서, 상기 초음파 추출은 건조된 동백나무의 과피(果皮) 분말, 백미꽃 분말, 또는 이들의 혼합물을 60% 내지 80% 에탄올 용액을 이용하여 상온에서 24시간 내지 72시간 동안 실시할 수 있다. 바람직하게는 65% 내지 75% 에탄올 용액을 이용하여 상온에서 36시간 내지 60시간 동안 실시하며, 보다 바람직하게는 70% 에탄올 용액을 이용하여 상온에서 48시간 동안 실시한다. 상기 수치의 하한을 벗어나는 경우 동백나무 과피 및 백미꽃에 함유된 본 발명의 유효성분이 충분히 추출되지 않으며 상한을 초과하는 경우 유효성분의 추출량에 유의적인 차이가 없고 상기 유효성분외 불순물이 추출되며 공정의 효율성이 감소하게 된다.As a specific example, the ultrasonic extraction can be performed on dried camellia bark powder, white rice flower powder, or a mixture thereof at room temperature for 24 to 72 hours using a 60% to 80% ethanol solution. there is. Preferably, it is carried out at room temperature for 36 to 60 hours using a 65% to 75% ethanol solution, and more preferably, it is carried out at room temperature for 48 hours using a 70% ethanol solution. If the value exceeds the lower limit of the above value, the active ingredient of the present invention contained in the camellia pericarp and white rice flower is not sufficiently extracted, and if the upper limit is exceeded, there is no significant difference in the amount of the active ingredient extracted, impurities other than the active ingredient are extracted, and process efficiency is increased. This decreases.
상기 수득한 동백나무 과피 추출물, 백미꽃 추출물, 및 이들의 복합 추출물은 이에 제한되지는 않으나, 진공감압농축기 또는 진공회전증발기를 이용하여 감압농축될 수 있다. 또한 감압농축 후 이에 제한되지는 않으나, 동결건조, 감압건조, 진공건조, 비등건조, 또는 분무건조를 통해 건조될 수 있다.The obtained Camellia pericarp extract, White rice flower extract, and their complex extracts are not limited thereto, but may be concentrated under reduced pressure using a vacuum concentrator or vacuum rotary evaporator. Additionally, after concentration under reduced pressure, it may be dried through, but not limited to, freeze-drying, reduced-pressure drying, vacuum drying, boiling drying, or spray drying.
본 발명의 상기 조성물은 동백나무 과피 추출물과 백미꽃 추출물 각각을 일정 중량비로 혼합하여 포함시키거나 동백나무 과피 및 백미꽃을 일정 중량비로 혼합하고 추출하여 포함시킬 수 있으며, 이를 편의상 "복합 추출물"이라고도 한다. 상기 "일정 중량비"는 동백나무 과피 추출물 또는 동백나무 과피와 백미꽃 추출물 또는 백미꽃을 0.8 내지 1.2: 0.8 내지 1.2의 중량비, 바람직하게는 0.9 내지 1.1: 0.9 내지 1.1의 중량비, 가장 바람직하게는 1: 1의 중량비이다. 상기 일정 중량비로 제조된 복합 추출물은 하기에서 서술하는 두피 가려움증 완화 효능, 두피 장벽 강화 효능, 및 두피 염증 유발 전염증성 사이토카인의 생성 억제 효능이 각각의 추출물과 대비하여 현저히 우수하며, 상기 중량비를 벗어나는 경우 상기한 효과가 감소하는 문제가 있다.The composition of the present invention may contain the camellia pericarp extract and the white rice flower extract by mixing each at a certain weight ratio, or the camellia pericarp and the white rice flower extract may be mixed and extracted at a constant weight ratio, and this is also referred to as a “composite extract” for convenience. The "constant weight ratio" refers to a weight ratio of Camellia pericarp extract or Camellia pericarp and White rice flower extract or White rice flower of 0.8 to 1.2: 0.8 to 1.2, preferably 0.9 to 1.1: 0.9 to 1.1, most preferably 1: 1. is the weight ratio of The complex extract prepared at the above-mentioned constant weight ratio is significantly superior to the individual extracts in the scalp itching alleviation effect, scalp barrier strengthening effect, and production inhibition effect of pro-inflammatory cytokines that cause scalp inflammation, which are described below, compared to the individual extracts. In this case, there is a problem that the above effect is reduced.
본 발명에 따른 동백나무 과피 추출물과 백미꽃 추출물의 복합 추출물은 두피에 발생한 가려움증, 두피의 장벽 약화로 인한 두피의 유분과 수분의 불균형, 두피의 염증 증가 등과 같은 문제성 두피를 정상적인 두피로의 개선 및 치료에 효과적이다. 이때 문제성 두피를 정상적인 두피로 걔선 또는 치료하는 과정 또는 문제성 두피를 정상적인 두피로 개선 또는 치료한 것을 "두피 진정"이라고 한다.The complex extract of the camellia pericarp extract and the white rice flower extract according to the present invention improves and treats problem scalps such as itchiness on the scalp, imbalance of oil and moisture in the scalp due to weakening of the scalp barrier, and increased inflammation of the scalp to a normal scalp. It is effective for At this time, the process of turning or treating a problematic scalp into a normal scalp, or improving or treating a problematic scalp into a normal scalp, is called “scalp soothing.”
하나의 구체적 예로서, 본 발명에 따른 동백나무 과피 추출물과 백미꽃 추출물의 복합 추출물은 비만세포의 히스타민 분비 억제 효과가 우수하므로 두피 가려움증 완화 또는 억제에 효과적이다.As a specific example, the composite extract of Camellia pericarp extract and White rice flower extract according to the present invention has an excellent effect of suppressing histamine secretion from mast cells and is therefore effective in alleviating or suppressing scalp itching.
상기 "두피 가려움증 완화" 또는 "두피 가려움증 억제"는 두피에 존재하는 말라세지아(Malasezia)에 의한 대사 잔여물에 의한 비만세포의 자극, 두피에 과도하게 생성된 피지 또는 비듬, 또는 지루성 두피염 등에 의하여 두피를 긁게 되는 생리적 현상을 감소시켜 두피의 긁음에 의한 상처를 발생시키지 않을 뿐만 아니라 두피의 긁음에 의해 발생한 상처에의 2차 세균 감염 등을 방지하게 하는 것을 말한다.The above-mentioned “alleviating scalp itching” or “suppressing scalp itching” refers to stimulation of mast cells by metabolic residues caused by Malasezia present in the scalp, sebum or dandruff excessively produced in the scalp, or seborrheic dermatitis. By reducing the physiological phenomenon of scratching the scalp, it not only prevents wounds caused by scalp scratching, but also prevents secondary bacterial infection in wounds caused by scalp scratching.
또 하나의 구체적 예로서, 본 발명에 따른 동백나무 과피 추출물과 백미꽃 추출물의 복합 추출물은 두피의 각질세포 내 필라그린(fillaggrin) 단백질의 생성을 촉진하므로 두피 장벽 강화에 효과적이다.As another specific example, the complex extract of camellia pericarp extract and white rice flower extract according to the present invention is effective in strengthening the scalp barrier because it promotes the production of filaggrin protein in the keratinocytes of the scalp.
상기 "두피 장벽"은 외부 미생물, 독성물질, 산화제, 자외선 등의 외부 오염물질의 두피 내 침입을 방어하고 두피 내 수분의 손실을 방지하는 역할을 하는 것을 말하는데, 이러한 두피 장벽의 강화는 두피의 각질세포 내 필라그린 단백질의 생성을 촉진함으로써 이루어질 수 있다.The "scalp barrier" refers to the role of protecting the scalp from invasion of external pollutants such as external microorganisms, toxic substances, oxidants, ultraviolet rays, etc., and preventing the loss of moisture within the scalp. This strengthening of the scalp barrier is achieved by strengthening the scalp's dead skin cells. This can be achieved by stimulating the production of filaggrin protein within cells.
또 다른 하나의 구체적 예로서, 본 발명에 따른 동백나무 과피 추출물과 백미꽃 추출물의 복합 추출물은 두피의 각질세포의 전염증성 사이토카인 발현 억제효과가 우수하여 두피 염증의 억제 또는 개선에 효과적이다.As another specific example, the complex extract of Camellia pericarp extract and White rice flower extract according to the present invention has an excellent effect of suppressing the expression of pro-inflammatory cytokines in keratinocytes of the scalp, and is therefore effective in suppressing or improving scalp inflammation.
상기 "두피 염증의 억제" 또는 "두피 염증의 개선"은 두피에 과도하게 생성된 피지나 비듬, 또는 두피의 가려움증에 의한 상처의 감염 등에 의해 발생하는 두피의 생체 내 반응을 감소시키는 것을 말한다.The term “inhibition of scalp inflammation” or “improvement of scalp inflammation” refers to reducing the in vivo reaction of the scalp caused by excessively produced sebum or dandruff on the scalp, or infection of a wound due to itching of the scalp.
따라서, 본 발명에 따른 동백나무 과피 추출물과 백미꽃 추출물을 유효성분으로 포함하는 상기 조성물은 히스타민 분비를 억제하고, 장벽기능을 강화하고, 전염증성 사이토카인의 생성을 억제하는 효과가 우수하여 두피 진정을 위한 조성물로 유용하다.Therefore, the composition containing the camellia pericarp extract and the white rice flower extract according to the present invention as active ingredients is excellent in suppressing histamine secretion, strengthening the barrier function, and suppressing the production of pro-inflammatory cytokines, thereby soothing the scalp. It is useful as a composition for
본 발명의 조성물에 있어서, 동백나무 과피 추출물과 백미꽃 추출물의 복합 추출물의 유효성분은 전체 조성물 중량을 기준으로 하여 0.0001 내지 10.0 중량%, 바람직하게는 0.001 내지 10.0 중량%, 보다 바람직하게는 0.01 내지 10.0 중량%, 보다 더 바람직하게는 0.1 내지 10.0 중량를 포함할 수 있다. 만일 복합 추출물의 상기 함량이 0.0001 중량% 미만인 경우에는 두피의 염증 및 가려움증 완화 효과 및 두피 장벽 강화 효과가 너무 미약하여 두피 진정에 유용하지 않으며, 10.0 중량%를 초과하는 경우에는 함량의 증가에 따른 효과의 증가가 미비하고 제형상의 안정성이 확보되지 않는 문제점이 있다.In the composition of the present invention, the active ingredient of the complex extract of Camellia pericarp extract and White rice flower extract is 0.0001 to 10.0% by weight, preferably 0.001 to 10.0% by weight, more preferably 0.01 to 10.0% by weight, based on the total weight of the composition. It may include weight%, more preferably 0.1 to 10.0 weight. If the above content of the complex extract is less than 0.0001% by weight, the effect of relieving inflammation and itchiness of the scalp and strengthening the scalp barrier is too weak to be useful for soothing the scalp, and if it exceeds 10.0% by weight, the effect increases as the content increases. There is a problem that the increase is insufficient and the stability of the formulation is not secured.
본 발명의 상기 화장료 조성물은 유효 성분인 동백나무 과피 추출물과 백미꽃 추출물 이외에 화장료 조성물에 통상적으로 이용되는 성분들을 포함하며, 예를 들어 항산화제, 용해화제, 안정화제, 비타민, 안료, 그리고 향료와 같은 통상적인 보조제 및 담체를 포함할 수 있다.The cosmetic composition of the present invention contains ingredients commonly used in cosmetic compositions in addition to the active ingredients, Camellia pericarp extract and White rice flower extract, such as antioxidants, solubilizers, stabilizers, vitamins, pigments, and fragrances. It may contain conventional auxiliaries and carriers.
본 발명의 상기 화장료 조성물은 당 업계에서 일반적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예컨데, 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클린싱, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션 및 스프레이 등으로 제형화될 수 있으나, 이에 한정되는 것은 아니다. 그 외, 영양 크림, 수렴 화장수, 유연 화장수, 로션, 에센스, 샴푸, 영양젤 또는 마사지 크림의 제형으로 제조될 수 있다.The cosmetic composition of the present invention can be prepared in any formulation commonly prepared in the art, for example, solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing, It may be formulated as oil, powder foundation, emulsion foundation, wax foundation, spray, etc., but is not limited thereto. In addition, it can be manufactured in the form of nutritional cream, astringent lotion, softening lotion, lotion, essence, shampoo, nutritional gel, or massage cream.
본 발명의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물성유, 식물성유, 왁스, 파라핀, 전분, 트라가칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation of the present invention is a paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tragacanth, cellulose derivatives, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide are used as carrier ingredients. It can be.
본 발명의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다.When the formulation of the present invention is a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, or polyamide powder can be used as the carrier ingredient. In particular, when the formulation is a spray, chlorofluorohydrocarbon and propane may be used as carrier ingredients. /May contain propellants such as butane or dimethyl ether.
본 발명의 제형이 용액 또는 유탁액인 경우에는 담체 성분으로서 용매, 용해화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌 글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 있다.When the formulation of the present invention is a solution or emulsion, a solvent, solubilizing agent or emulsifying agent is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 , 3-butyl glycol oil, glycerol aliphatic esters, polyethylene glycol or fatty acid esters of sorbitan.
본 발명의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라가칸트 등이 이용될 수 있다.When the formulation of the present invention is a suspension, the carrier ingredients include water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester, and polyoxyethylene sorbitan ester, and microcrystals. Cellulose, aluminum metahydroxide, bentonite, agar, or tragacanth can be used.
본 발명의 제형이 계면-활성제 함유 클린징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성 유, 라놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.When the formulation of the present invention is a surfactant-containing cleansing agent, the carrier ingredients include aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyl taurate, sarcosinate, and fatty acid amide. Ether sulfate, alkylamidobetaine, fatty alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, lanolin derivative, or ethoxylated glycerol fatty acid ester can be used.
특히, 본 발명의 상기 화장료 조성물은 두피에 도포하여 두피의 염증 및 가려움증을 완화하고 두피의 장벽을 강화하여 두피를 진정하는 헤어케어용 화장료 조성물로서 제공될 수 있다.In particular, the cosmetic composition of the present invention can be provided as a hair care cosmetic composition that relieves inflammation and itching of the scalp by applying it to the scalp and soothes the scalp by strengthening the scalp barrier.
상기 헤어케어용 화장료 조성물은 예를 들면, 헤어샴푸, 헤어 린스, 헤어컨디셔너, 헤어트리트먼트, 헤어토닉, 스칼프트리트먼트, 헤어로션, 헤어크림, 헤어미스트, 헤어앰플, 헤어 팩, 헤어에센스, 헤어오일, 두피스케일러, 모발 영양화장수 및 헤어 염색제 등이 있다.The cosmetic composition for hair care includes, for example, hair shampoo, hair rinse, hair conditioner, hair treatment, hair tonic, scalp treatment, hair lotion, hair cream, hair mist, hair ampoule, hair pack, hair essence, hair There are oils, scalp scalers, hair nourishing lotions, and hair dyes.
한편, 본 발명의 유효성분인 동백나무 과피 추출물과 백미꽃 추출물의 복합 추출물은 피부누적 자극시험 결과 인체에 무해한 물질임이 밝혀졌다. 따라서 본 발명의 동백나무 과피 추출물과 백미꽃 추출물의 복합 추출물물은 독성 및 부작용이 거의 없으므로 장기간 사용 시에도 안심하고 사용할 수 있으므로, 화장료에 안전하게 사용할 수 있다.Meanwhile, the active ingredient of the present invention, a complex extract of camellia pericarp extract and white rice flower extract, was found to be a substance harmless to the human body as a result of a cumulative skin irritation test. Therefore, the composite extract of the camellia pericarp extract and the white rice flower extract of the present invention has almost no toxicity and side effects, so it can be used safely even for long-term use, and can be safely used in cosmetics.
이하, 본 발명의 이해를 돕기 위하여 실시예 등을 들어 상세하게 설명하기로 한다. 그러나, 본 발명에 따른 실시예들은 여러 가지 다른 형태로 변형될 수 있으며, 본 발명의 범위가 하기 실시예들에 한정되는 것으로 해석되어서는 안 된다. 본 발명의 실시예들은 당업계에서 평균적인 지식을 가진 자에게 본 발명을 보다 완전하게 설명하기 위해 제공되는 것이다.Hereinafter, to aid understanding of the present invention, it will be described in detail through examples. However, the embodiments according to the present invention may be modified into various other forms, and the scope of the present invention should not be construed as being limited to the following embodiments. Embodiments of the present invention are provided to more completely explain the present invention to those skilled in the art.
실시예 1: 두피진정 및 개선 효능을 가지는 천연물의 선정Example 1: Selection of natural products with scalp soothing and improving effects
문제성 두피 개선에 관한 선행연구결과를 바탕으로 동백나무 과피 및 백미꽃을 선별하였고, 이들로부터 수득한 추출물의 염증인자생성 억제, 히스타민 분비 억제 및 장벽 기능강화 효능에 대해서 검증하였다.Based on the results of previous research on improving problematic scalp, camellia pericarp and white rice flower were selected, and the extracts obtained from them were verified for their efficacy in suppressing inflammatory factor production, histamine secretion, and strengthening barrier function.
1-1. 동백나무 과피 추출물의 제조1-1. Preparation of Camellia pericarp extract
동백나무 열매에서 씨앗을 분리하고 남은 과피를 이물질 및 불순물이 완전히 제거되도록 깨끗이 세척한 후, 20℃ 내지 35℃에서 음건한 다음 입자의 크기가 1㎜ 이하가 되도록 분쇄하였다. 그 후 상기 분쇄된 동백나무 과피 분말 1 ㎏을 70% 에탄올 용매에 담근 후 48시간 동안 초음파 추출한 다음 수득한 추출액을 여과지(Advantec, No.2)를 사용하여 여과하였다. 상기 여과물을 감압 농축하여 에탄올 용매를 제거한 후 동결건조하여 동백나무 과피 추출물 파우더를 제조하였다.The seeds were separated from the camellia fruit, and the remaining skin was washed thoroughly to completely remove foreign substances and impurities, dried in the shade at 20°C to 35°C, and then ground to a particle size of 1 mm or less. Afterwards, 1 kg of the pulverized camellia rind powder was immersed in 70% ethanol solvent and subjected to ultrasonic extraction for 48 hours, and the obtained extract was filtered using filter paper (Advantec, No. 2). The filtrate was concentrated under reduced pressure to remove the ethanol solvent and then freeze-dried to prepare camellia rind extract powder.
1-2. 백미꽃 추출물의 제조1-2. Preparation of white rice flower extract
백미꽃 지상부를 이물질 및 불순물이 완전히 제거되도록 깨끗이 세척한 후, 20℃ 내지 35℃에서 음건한 다음 입자의 크기가 1㎜ 이하가 되도록 분쇄하였다. 그 후 상기 분쇄된 백미꽃 분말 1 ㎏을 70% 에탄올 용매에 담근 후 48시간 동안 초음파 추출한 다음 수득한 추출액을 여과지(Advantec, No.2)를 사용하여 여과하였다. 상기 여과물을 감압 농축하여 에탄올 용매를 제거한 후 동결건조하여 백미꽃 추출물 파우더를 제조하였다.The aerial parts of white rice flowers were thoroughly washed to completely remove foreign substances and impurities, dried in the shade at 20°C to 35°C, and then ground to a particle size of 1 mm or less. Thereafter, 1 kg of the pulverized white rice flower powder was immersed in 70% ethanol solvent and subjected to ultrasonic extraction for 48 hours, and the obtained extract was filtered using filter paper (Advantec, No. 2). The filtrate was concentrated under reduced pressure to remove the ethanol solvent and then freeze-dried to prepare white rice flower extract powder.
1-3. 동백나무 과피 추출물과 백미꽃 추출물을 포함하는 복합 추출물 제조1-3. Manufacture of complex extract containing camellia rind extract and white rice flower extract
상기 1-1의 동백나무과피 추출물과 1-2의 백미꽃 지상부 추출물을 1:1의 중량비로 혼합하여 복합 추출물을 제조하였다.A composite extract was prepared by mixing the Camellia pericarp extract of 1-1 and the above-mentioned aerial part of white rice flower extract of 1-2 at a weight ratio of 1:1.
실시예 2: 인 비트로(Example 2: In vitro ( in vitroin vitro )에서 복합 추출물의 히스타민 분비 억제 효과 측정) Measurement of histamine secretion inhibition effect of complex extract
두피 가려움을 유도하는 히스타민에 대해 복합 추출물이 어떠한 영향을 미치는지 알아보기 위해 히스타민 유리 억제능을 측정하였다.To determine the effect of the complex extract on histamine, which induces scalp itching, the ability to inhibit histamine release was measured.
구체적으로, 마우스의 비만세포인 MC/9 세포(mouse mast cell line, ATCC)를 10% Rat T-STIM, 10% FBS, 0.05mM 2-머캅토에탄올이 포함된 DMEM 배지 배양하였다. MC/9 세포를 회수하여 Tyrode HEPES buffer로 현탁시킨 후 24-웰 플레이트에 웰 당 1 × 106 세포수로 분주하였다. 복합 추출물과 백미꽃 추출물, 동백나무 과피 추출물을 각각 1시간 동안 전처리한 다음 100 μM 농도의 올레인산을 처리하여 3시간 동안 다시 배양하였다. 3시간 배양 후 원심 분리하여 세포배양 상등액만을 수집하여 샘플을 준비하였다. 히스타민 측정 키트 (Histamine ELISA kit, Enzo, 미국)를 이용하여 유리되는 히스타민의 양을 측정하였다. 자세한 실시방법은 Enzo사의 키트 설명서에 따라 수행하였다. 유리되는 히스타민의 수치는 히스타민 표준곡선에 대비하여 그 양을 환산하였으며, 그 결과를 도 1에 나타내었다.Specifically, MC/9 cells (mouse mast cell line, ATCC), which are mouse mast cells, were cultured in DMEM medium containing 10% Rat T-STIM, 10% FBS, and 0.05mM 2-mercaptoethanol. MC/9 cells were recovered, suspended in Tyrode HEPES buffer, and distributed at 1 × 10 6 cells per well in a 24-well plate. The composite extract, white rice flower extract, and camellia pericarp extract were each pretreated for 1 hour, then treated with oleic acid at a concentration of 100 μM and incubated again for 3 hours. After 3 hours of incubation, samples were prepared by centrifuging and collecting only the cell culture supernatant. The amount of histamine released was measured using a histamine measurement kit (Histamine ELISA kit, Enzo, USA). The detailed implementation method was performed according to Enzo's kit instructions. The level of liberated histamine was converted to the amount compared to the histamine standard curve, and the results are shown in Figure 1.
도 1에서 보듯이, 올레인산에 의해 증가된 비만세포의 히스타민 유리는 백미꽃 추출물을 단독으로 100 ppm 처리한 경우 약 7.3% 정도 억제되었고, 동백나무과피 추출물을 단독으로 100 ppm 처리한 경우 약 63.2% 정도 억제되었으며, 복합 추출물을 100 ppm으로 처리한 경우 약 82.5% 정도의 억제되는 효능을 나타내었다. 따라서, 복합 추출물이 각각의 추출물에 비하여 매우 우수한 비만세포의 히스타민 유리 억제 효능을 나타내고 있음을 알 수 있었다.As shown in Figure 1, histamine release from mast cells increased by oleic acid was suppressed by about 7.3% when treated with 100 ppm of white rice flower extract alone, and by about 63.2% when treated with 100 ppm of Camellia pericarp extract alone. It was inhibited, and when the complex extract was treated at 100 ppm, the inhibition effect was about 82.5%. Therefore, it was found that the composite extract showed a very superior efficacy in inhibiting histamine release from mast cells compared to the individual extracts.
실시예 3: 인 비트로(Example 3: In vitro ( in vitroin vitro )에서 복합 추출물의 소듐라우릴설페이트 유래 전염증성 사이토카인 생성 억제 효과) Inhibitory effect on the production of pro-inflammatory cytokines derived from sodium lauryl sulfate of the complex extract.
두피 염증을 유발하는 전염증성 사이토카인에 대해 복합 추출물이 어떠한 영향을 미치는지에 알아보기 위해 전염증성 사이토카인 생성 억제능을 측정하였다.To determine the effect of the complex extract on pro-inflammatory cytokines that cause scalp inflammation, the ability to inhibit pro-inflammatory cytokine production was measured.
구체적으로, 인간의 Human epidermal keratinocytes (HEKn, Thermo Fisher, 미국)를 Human Keratinocyte Growth Supplement (HKGS, Thermo Fisher, 미국)가 포함된 EpiLife Medium(Thermo Fisher, 미국)에 배양하였다. HEKn을 웰 당 2 × 104 세포수로 24-웰 플레이트에 seeding하여 웰을 70% 이상 덮을 때까지 배양하였다. HKGS가 미 포함된 EpiLife Medium으로 교환해 준 HEKn에 복합 추출물을 1시간 동안 전처리한 다음 100 μM 농도의 소듐라우릴셀페이트(sodium lauryl sulfate, SLS)를 처리하여 24시간 동안 다시 배양하였다. 24시간 배양 후 세포배양액을 수집하여 샘플을 준비하였다. TNF-a와 IL-1b 측정 ELISA kit (R&D Systems, 미국)를 이용하여 소듐라우릴설페이트 처리로부터 생성되는 TNF-α, IL-1β 생성 양을 측정하였다. 자세한 실시방법은 R&D Systems사의 키트 설명서에 따라 수행하였다. 유리되는 TNF-α와 IL-1β의 수치는 각각의 표준곡선에 대비하여 그 양을 환산하였으며, 그 결과를 도 2에 나타내었다.Specifically, human epidermal keratinocytes (HEKn, Thermo Fisher, USA) were cultured in EpiLife Medium (Thermo Fisher, USA) containing Human Keratinocyte Growth Supplement (HKGS, Thermo Fisher, USA). HEKn were seeded in a 24-well plate at 2 × 10 4 cells per well and cultured until more than 70% of the wells were covered. HEKn, which was exchanged for EpiLife Medium without HKGS, was pretreated with the complex extract for 1 hour, then treated with 100 μM sodium lauryl sulfate (SLS) and cultured again for 24 hours. After 24 hours of incubation, cell culture fluid was collected and samples were prepared. The amount of TNF-α and IL-1β produced from sodium lauryl sulfate treatment was measured using an ELISA kit for measuring TNF-a and IL-1b (R&D Systems, USA). The detailed implementation method was carried out according to the kit instructions from R&D Systems. The levels of free TNF-α and IL-1β were converted to each standard curve, and the results are shown in Figure 2.
도 2에서 보듯이, 소듐라우릴설페이트에 의해 증가된 HEKn의 전염증성 사이토카인(TNF-α, IL-1β)의 생성이 복합 추출물에 의해 농도의존적으로 억제되었으며, 복합 추출물을 100 ppm으로 처리하였을 때 TNF-α는 약 76.3%, IL-1β는 75% 정도의 억제되는 효능을 나타내었다.As shown in Figure 2, the production of pro-inflammatory cytokines (TNF-α, IL-1β) in HEKn, which was increased by sodium lauryl sulfate, was suppressed in a concentration-dependent manner by the complex extract, when the complex extract was treated at 100 ppm. When TNF-α is about 76.3% and IL-1β is about 75% It showed a certain level of inhibitory efficacy.
실시예 4: 인 비트로(Example 4: In vitro ( in vitroin vitro )에서 복합 추출물의 필라그린 발현 촉진 효과) Effect of complex extract on promoting filaggrin expression
두피 장벽 기능 강화에 대해 복합 추출물이 어떠한 영향을 미치는지에 알아보기 위해 필라그린의 생성 촉진능을 측정하였다.To determine the effect of the complex extract on strengthening scalp barrier function, the ability to promote filaggrin production was measured.
구체적으로, 인간의 각질세포인 Human epidermal keratinocytes (HEKn, Thermo Fisher, 미국)를 Human Keratinocyte Growth Supplement (HKGS, Thermo Fisher, 미국)가 포함된 EpiLife Medium(Thermo Fisher, 미국)에 배양하였다. HEKn을 웰 당 2 × 105 세포수로 6-웰 플레이트에 seeding하여 웰을 70% 이상 덮을 때까지 배양하였다. HKGS가 미 포함된 EpiLife Medium으로 교환해 준 HEKn에 복합 추출물을 농도별로 처리하여 60시간 동안 다시 배양하였다. 양성 대조군으로는 1.5 mM CaCl2를 처리하였다. 60시간 배양 후 세포를 회수하여 RNeasy kit (Qiagen, 독일)를 이용하여 tRNA를 추출하였다. 추출한 tRNA는 AccuPower® RT PreMix & Master Mix (Bioneer, 한국)를 이용하여 cDNA를 합성하였다. 합성한 cDNA는 실시간 중합효소 연쇄반응 (quantitative real time PCR, Applied Biosystems, 미국)을 이용하여 필라그린의 mRNA 발현 정도를 측정하였다. 필라그린의 mRNA 발현 정도는 하우스키핑유전자(housekeeping gene)인 글리세르알데하이드-3-인산탈수소효소(Glyceraldehyde 3-phosphate dehydrogenase, GAPDH)의 발현과 대비하여 그 정도를 fold로 환산하였으며, 그 결과를 도 3에 나타내었다.Specifically, human epidermal keratinocytes (HEKn, Thermo Fisher, USA), which are human keratinocytes, were cultured in EpiLife Medium (Thermo Fisher, USA) containing Human Keratinocyte Growth Supplement (HKGS, Thermo Fisher, USA). HEKn were seeded in a 6-well plate at 2 × 10 5 cells per well and cultured until more than 70% of the wells were covered. HEKn, which had been exchanged for EpiLife Medium without HKGS, was treated with the complex extract at different concentrations and cultured again for 60 hours. As a positive control, 1.5mM CaCl 2 was treated. After culturing for 60 hours, cells were recovered and tRNA was extracted using the RNeasy kit (Qiagen, Germany). The extracted tRNA was synthesized into cDNA using AccuPower ® RT PreMix & Master Mix (Bioneer, Korea). The synthesized cDNA was used to measure the mRNA expression level of filaggrin using quantitative real time PCR (Applied Biosystems, USA). The mRNA expression level of filaggrin was converted to fold by comparing it with the expression of glyceraldehyde 3-phosphate dehydrogenase (GAPDH), a housekeeping gene, and the results are shown in Figure 2. It is shown in 3.
도 3에서 보듯이, 필라그린의 생성이 음성 대조군인 무처리군과 비교하여 복합 추출물 100 ppm 처리시 약 3.7 fold 정도 촉진되는 결과를 나타내었으며, 양성 대조군인 CaCl2와 비교하여 거의 유사한 효능을 나타내었다.As shown in Figure 3, the production of filaggrin was promoted by about 3.7 fold when treated with 100 ppm of the complex extract compared to the untreated group, which was the negative control, and showed almost similar efficacy compared to CaCl 2 , which was the positive control. It was.
실시예 5: 복합 추출물의 인체 피부에 대한 안전성 확인 시험Example 5: Safety confirmation test of complex extract on human skin
본 발명에 따른 복합 추출물이 인체피부에 안전한지 확인하기 위하여 피부 안전성 검증 실험을 수행하였다. 이를 위해 피부누적자극시험을 실시하였다. A skin safety verification experiment was performed to confirm whether the complex extract according to the present invention was safe for human skin. For this purpose, a skin cumulative irritation test was conducted.
실시예 1의 복합 추출물을 각각 0.1%, 0.5% 및 1%를 함유한 영양 크림을 제조하였다. 구체적으로, 수상인 정제수, 트리에탄올아민 및 프로필렌 글리콜을 70℃로 가열하고 용해시킨 후, 밀납, 유동파라핀, 유상성분, 유화제 및 방부제를 70℃로 가열하여 용해한 액을 첨가하여 유화시켰다. 유화가 완료된 후 상기 용액을 45℃로 냉각시키고 복합 추출물 각각 0.1%, 0.5% 및 1% 첨가하고 분산시킨 다음 30℃로 냉각하였다. 상기 복합 추출물의 함량을 0.1%, 0.5% 및 1%로 증가시킴에 따라서 유동파라핀의 함량을 각각 9.91%, 9.51% 및 9.01%로 줄여가며 영양크림을 제조하였다.A nutritious cream containing 0.1%, 0.5%, and 1% of the complex extract of Example 1, respectively, was prepared. Specifically, purified water, triethanolamine, and propylene glycol as aqueous phase were heated to 70°C and dissolved, and then beeswax, liquid paraffin, oil phase ingredients, emulsifier, and preservative were added and emulsified. After emulsification was completed, the solution was cooled to 45°C, 0.1%, 0.5%, and 1% of the composite extract were added and dispersed, respectively, and then cooled to 30°C. As the content of the complex extract was increased to 0.1%, 0.5%, and 1%, the nutritional cream was prepared by reducing the liquid paraffin content to 9.91%, 9.51%, and 9.01%, respectively.
상기와 같이 제조한 영양크림을 사용하여 건강한 30명의 성인을 대상으로 윗 팔뚝 부위에 격일로 총 9회의 24시간 누적 첩포를 시행하여 복합 추출물이 피부에 자극을 주는지의 여부를 측정하였다.Using the nutritive cream prepared as above, 30 healthy adults were applied to the upper forearm area 9 times a cumulative patch for 24 hours every other day to measure whether the complex extract irritates the skin.
첩포 방법은 핀 챔버(Finn chamber, Epitest Ltd, 핀란드)를 이용하였다. 챔버에 상기 각 피부 외용제를 15㎕씩 적하한 후 첩포를 실시하였다. 매회 피부에 나타난 반응의 정도를 하기 [수학식 2]를 이용하여 점수화 하였으며, 그 결과를 하기 표 1에 나타내었다.The patch method used a Finn chamber (Epitest Ltd, Finland). 15 ㎕ of each skin external preparation was added dropwise to the chamber, and then a patch was applied. The degree of reaction on the skin each time was scored using the following [Equation 2], and the results are shown in Table 1 below.
[수학식 2][Equation 2]
평균반응도 = [[(반응지수 × 반응도)/(총 피검자수 × 최고점수(4점))] × 100] ÷ 검사 횟수(9회)Average reactivity = [[(response index × reactivity)/(total number of subjects × highest score (4 points))] × 100] ÷ number of tests (9)
반응도에서 ±는 1점, +는 2점 및 ++는 4점의 점수를 부여하며, 평균반응도가 3 미만일 때 안전한 조성물로 판정된다.In reactivity, ± is given a score of 1 point, + is 2 points, and ++ is given a score of 4 points, and when the average reactivity is less than 3, the composition is judged to be safe.
반응도average
Responsiveness
대조군
control group
(0.1 %)complex extract
(0.1%)
(0.5%)complex extract
(0.5%)
(1%)complex extract
(One%)
상기 표 1에 나타난 바와 같이, 시험군 1, 2 및 3 모두 ±, + 및 ++에 해당하는 사람의 수가 모두 0명이고, 평균 반응도 역시 0.00이었다. 상기 시험결과 3 이하의 평균반응도를 나타내므로, 본 발명에 따른 동백나무 과피 추출물은 뚜렷한 누적자극 양상을 나타내지 않는 인체 피부에 안전한 물질로 판정되었다.As shown in Table 1, in test groups 1, 2, and 3, the number of people corresponding to ±, +, and ++ was 0, and the average response was also 0.00. Since the test results showed an average reactivity of 3 or less, the camellia pericarp extract according to the present invention was determined to be a safe material for human skin without showing a clear cumulative irritation pattern.
본 발명의 조성물은 하기와 같이 제제예로 제조될 수 있으나, 이에 한정되는 것은 아니다.The composition of the present invention can be prepared as a formulation example as follows, but is not limited thereto.
제제예 1: 화장료 제제Formulation Example 1: Cosmetic formulation
1-1: 유연화장수1-1: Soft lotion
하기의 표 2와 같이 복합 추출물을 유효성분으로 포함하는 유연화장수를 통상의 방법에 따라 제조하였다.As shown in Table 2 below, a softening lotion containing a complex extract as an active ingredient was prepared according to a conventional method.
1-2: 마사지 크림1-2: Massage Cream
하기의 표 3과 같이 실시예 1의 복합 추출물을 유효성분으로 포함하는 마사지크림을 통상의 방법에 따라 제조하였다.As shown in Table 3 below, a massage cream containing the complex extract of Example 1 as an active ingredient was prepared according to a conventional method.
1-3: 팩1-3: Pack
하기의 표 4와 같이 실시예 1의 복합 추출물을 유효성분으로 포함하는 팩을 통상의 방법에 따라 제조하였다.As shown in Table 4 below, a pack containing the complex extract of Example 1 as an active ingredient was prepared according to a conventional method.
1-4: 샴푸1-4: Shampoo
하기의 표 5와 같이 복합 추출물을 유효성분으로 포함하는 샴푸를 통상의 방법에 따라 제조하였다.As shown in Table 5 below, shampoo containing the complex extract as an active ingredient was prepared according to a conventional method.
1-5: 린스1-5: Rinse
하기의 표 6과 같이 복합 추출물을 유효성분으로 포함하는 린스를 통상의 방법에 따라 제조하였다.As shown in Table 6 below, a rinse containing the complex extract as an active ingredient was prepared according to a conventional method.
1-6: 팩1-6: Pack
하기의 표 7과 같이 복합 추출물을 유효성분으로 포함하는 팩을 통상의 방법에 따라 제조하였다.As shown in Table 7 below, a pack containing the complex extract as an active ingredient was prepared according to a conventional method.
1-7: 헤어 세럼1-7: Hair Serum
하기의 표 8과 같이 복합 추출물을 유효성분으로 포함하는 헤어 세럼을 통상의 방법에 따라 제조하였다.As shown in Table 8 below, hair serum containing the complex extract as an active ingredient was prepared according to a conventional method.
제제예 2: 약제학적 제제Formulation Example 2: Pharmaceutical formulation
2-1: 젤의 제조2-1: Preparation of gel
2-2: 연고제의 제조2-2: Preparation of ointment
Claims (6)
Publications (1)
Publication Number | Publication Date |
---|---|
KR20240105664A true KR20240105664A (en) | 2024-07-08 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100771829B1 (en) | A composition comprising plant extracts for protecting skin from stress due to harmful environment | |
KR101387308B1 (en) | Skin whitening composition by using of dendropanax morbifera ferment extract | |
KR101425031B1 (en) | Cosmetic composition for anti-irritation and skin moisturization containing Citrus junos Siebold seed oil and Mangifera Indica seed oil | |
US8986755B1 (en) | Skin moisturizer | |
KR20190023200A (en) | Low irritating cosmetic composition for skin whitening | |
KR100702327B1 (en) | Cosmetic material including extract of camellia flower for skin abirritation | |
KR102169463B1 (en) | Cosmetic composition for improving skin troubles | |
KR100754748B1 (en) | Compositiion for Inhibiting 5?-Reductase Activity and Cosmetic Composition for Inhibiting Secretion of Sebum containing Extract of Ulmus davidiana as Active Ingredient | |
KR100638053B1 (en) | Cosmetic composition for abirritating skin containing extract of rumex crispus as active ingredient | |
KR101350292B1 (en) | Cosmetic composition containing fermented extracts of panax ginseng root, ganoderma lucidum and white tea and method for preparing the same | |
KR102226179B1 (en) | Cosmetic Compositions for Anti-aging Comprising Extracts of Plants | |
KR101934976B1 (en) | Composition for enhancing skin barrier comprising mixture of Diospyros lotus leaf extract and Curcuma longa extract as effective component | |
KR20130066466A (en) | Cosmetic composition comprising the mixed extracts of achillea, borage, helichrysum, lady's mantle, and eucalyptus | |
KR20200129888A (en) | Cosmetic composition containing black kelp | |
KR101367703B1 (en) | Composition of cosmetic and treating skin disease | |
KR102323174B1 (en) | Cosmetic composition for alleviating skin trouble | |
KR20180137151A (en) | Cosmetic composition for preventing photo aging comprising Curcuma longa Linne leaf and Hibiscus manihot extracts | |
KR20240105664A (en) | Cosmetic composition for scalp soothing comprising mixture of Camellia japonica pericarp extract and Cynanchum atratum extract as an active ingredient | |
KR100589667B1 (en) | Compositions of cosmetics for atopy skin containing specific oriental herbal extracts | |
KR100946584B1 (en) | Cosmetic Composition Comprising Poncirus trifoliata fruit extract and Nymphaea caerulea extract | |
KR101081585B1 (en) | Cosmetic composition containing extract of ligustrum japonicum and hemerocallis fulva for improving skin wrinkle | |
KR101879315B1 (en) | A composition for skin smoothing comprising natural complex extracts | |
KR20150052907A (en) | Cosmetic composition for Improving Skin Moisturization Comprising the mixed extract of Peach blossom, Sophora japonica flower, Rhubarb and Clove buds as active ingredient | |
KR101987420B1 (en) | Cosmetic composition for skin moisturizing and skin soothing comprising dioscorea villosa, sesame indicum, saussurea involucrata and lonicera japonica extract | |
KR100927970B1 (en) | Sebum secretion containing acryl extract as an active ingredient and acne relief cosmetic composition |